報價延遲最少15分鐘:2025/08/25 04:52 EDT
盤前時段
|
||||
|
2.97 
|
|
|
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
3.02
|
|
|
| 價值評估 |
|
盈利(現時/預測)
33.63/-2.67
|
|
企業價值
5.17M
|
| 資產負債 |
|
每股賬面淨值
5.53
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
22.00K
|
|
每股收益
0.07
|
|
同行比較
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
報價延遲最少15分鐘：2025/08/25 04:52 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Catheter Precision Inc is engaged in design, manufacture and sale of new and innovative medical technologies primarily focused in the field of cardiac electrophysiology, or EP. The Company's primary product is the View into Ventricular Onset System (VIVO or VIVO System), which is a non-invasive imaging system that offers 3D cardiac mapping to help with localizing the sites of origin of idiopathic ventricular arrhythmias in patients with structurally normal hearts prior to EPprocedures. The VIVO system has achieved a CE Mark allowing it to be commercialized in the European Union and has been placed at several hospitals in Europe. Its newest product, the Surgical Vessel Closing Pressure Device (LockeT), is a suture retention device indicated for wound healing by distributing suture tension. |
